Key Details
Price
$14.23Last Dividend
$0.10Annual ROE
21.78%Beta
0.36Events Calendar
Next earnings date:
Jan 30, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
May 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
July 30, 2024Next split:
N/ARecent split:
Nov 05, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. announced the launch of Toripalimab in India.
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2025 Earnings Conference Call November 5, 2024 9:00 AM ET Company Participants Richa Periwal - Head of Investor Relations MV Narasimham - Chief Financial Officer Erez Israeli - Chief Executive Officer Conference Call Participants Kunal Dhamesha - Macquarie Neha Manpuria - Bank of America Amey Chalke - JM Financial Mikaela Franceschina - Barclays Harith Ahmad - Avendus Spark Damayanti Kerai - HSBC Bino Pathiparampil - Elara Capital Surya Patra - PhillipCapital Tarang Agarwal - Old Bridge Kunal Randeria - Axis Capital Anubhav Agarwal - UBS Vishal Manchanda - Systematix Operator Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries.
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Dr. Reddy's Laboratories stock has risen 29% since my last publication, with additional tailwinds from legislative changes and strong business momentum. The company's enduring competitive advantage as a generics pharmaceutical manufacturer produces abnormally high and persistent returns on capital. Quarterly insights show growth in U.S. generics, Europe, and India markets, with high-quality economic characteristics supporting $107/share intrinsic value.
Erez Israeli of Dr. Reddy's Laboratories says the company is "absolutely planning to play" in the biologics space, and while the U.S. remains a key market for the company, India and other markets will grow faster.
Dr. Reddy's (RDY) reports mixed first-quarter fiscal 2025 results, wherein earnings lag estimates, but revenues beat the same, driven by growth in global generics sales in North America and India.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #DRREDDY--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2024.
Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #CEO--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
FAQ
- What is the primary business of Dr Reddys Laboratories Limited?
- What is the ticker symbol for Dr Reddys Laboratories Limited?
- Does Dr Reddys Laboratories Limited pay dividends?
- What sector is Dr Reddys Laboratories Limited in?
- What industry is Dr Reddys Laboratories Limited in?
- What country is Dr Reddys Laboratories Limited based in?
- When did Dr Reddys Laboratories Limited go public?
- Is Dr Reddys Laboratories Limited in the S&P 500?
- Is Dr Reddys Laboratories Limited in the NASDAQ 100?
- Is Dr Reddys Laboratories Limited in the Dow Jones?
- When was Dr Reddys Laboratories Limited's last earnings report?
- When does Dr Reddys Laboratories Limited report earnings?